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Abstract
Tuberculosis (TB) and HIV comorbidity is a major challenge in TB prevention and control but difficult to assess in Germany as
in other countries, where data confidentiality precludes notifying the HIV status of TB patients. We aimed to estimate the
HIV-prevalence in TB patients in Germany, 2002–2009, and to characterize the HIV/TB patients demographically. Data from
the long-term observational open multicentre cohort ClinSurv HIV were used to identify incident TB in HIV-positive
individuals. We assessed the cohort’s coverage for the nationwide HIV-positive population by contrasting ClinSurv HIV
patients under antiretroviral therapy (ART) with national HIV patient numbers derived from ART prescriptions (data by
Insight Health; available for 2006–2009). The HIV-prevalence in TB patients was calculated as the number of HIV/TB cases
projected for Germany over all culture-positive TB notifications. From 2002 to 2009, 298 of 15,531 HIV-positive patients
enrolled in the ClinSurv HIV cohort were diagnosed with TB. A 21% cohort coverage was determined. The annual estimates
of the HIV-prevalence in TB patients were on average 4.5% and ranged from 3.5% (95%CI 2.3–5.1%) in 2007 to 6.6% (95%CI
5.0–8.5%) in 2005. The most recent estimate for 2009 was 4.0% (95%CI 2.6–5.9%). The 298 HIV/TB patients were
characterized by a male-to-female ratio of 2.1, by a median age of 38 years at TB diagnosis, and by 59% of the patients
having a foreign origin, mainly from Subsahara Africa. We provide, to our knowledge, the first estimate of the HIV-
prevalence in TB patients for Germany by joint evaluation of anonymous HIV and TB surveillance data sources. The
identified level of HIV in TB patients approximates available surveillance data from neighbouring countries and indicates a
non-negligible HIV/TB burden in Germany. Our estimation approach is valuable for epidemiological monitoring of HIV/TB
within the current legal frameworks.
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Introduction
Tuberculosis (TB) and HIV comorbidity is a relevant public
health issue worldwide and does not spare the European region
[1–3]. HIV/TB is considered a leading cause, together with multi-
and extensively drug resistant tuberculosis (M/XDR-TB), impair-
ing success in TB control [4,5]. Both HIV and TB adversely
interact when affecting the same patient: TB as an AIDS-defining
disease is a major cause of morbidity and mortality in people living
with HIV (PLWH) [1,6]. HIV-positive individuals infected with
Mycobacterium (M.) tuberculosis complex bacteria are placed at a 20
to 30 times greater risk of developing active TB [7–9]; moreover,
they are more prone to endogenous reactivation or exogenous
reinfection than HIV-negative individuals [7,8,10,11]. Diagnosis
of latent infection and active TB is more challenging in
immunocompromised individuals including PLWH [12]. They
may present with atypical clinical manifestations of TB or have
masked disease with implications on adequate clinical case
management [12,13].
The need for systematic HIV/TB surveillance including the
monitoring of the level of routine testing has been internationally
recognized. The strategic environment was decisively shaped by
the ‘‘Interim policy on collaborative TB/HIV activities’’ launched
in 2004 by the WHO [14] (latest update in 2012 [15]) advocating
three main areas of activities: A. establishing the mechanisms for
collaboration between TB and HIV programmes; B. decrease the
burden of TB in PLWH; and C. decrease the burden of HIV in
TB patients.
The European region was specifically addressed with the
‘‘Berlin Declaration on Tuberculosis’’ of the WHO European
Ministerial Forum [5], the ‘‘European Framework to decrease the
burden of TB/HIV’’ [16], and the ‘‘Framework Action Plan to
fight tuberculosis in the European Union’’ [17], adding authority
on collaboration between TB and HIV/AIDS national pro-
grammes and joint surveillance. Through the ‘‘Global Plan to Stop
TB’’ all WHO member states were requested to provide
information on HIV-prevalence among new TB notifications by
the year 2010 [18]. However, levels of implementing routine
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HIV/TB surveillance have remained heterogeneous in European
Union/European Economic Area (EU/EEA) member states. For
2010, only 18/30 EU/EEA member states, excluding Germany,
provided data on HIV among TB patients to the European Centre
for Disease Prevention and Control (ECDC) [19].
In Germany, both HIV infections and active TB are of
recognized public health relevance [20]. Mandatory notification
according to the German Protection against Infection Act [21]
resulted in 3.5 new HIV cases and 5.3 active TB cases per 100,000
population in 2011 [22]. However, their reporting channels are
separate: TB cases are notified by name to local public health
offices and anonymously transmitted via State health departments
to the national level, the Robert Koch Institute (RKI). HIV
diagnoses are anonymously notifiable directly to the RKI. Data
confidentiality legislation precludes recording the HIV status of
TB patients in national TB notification data. HIV surveillance
instruments may however include information on TB as AIDS-
defining disease.
With this study, we aimed to estimate the HIV-prevalence in
TB patients in Germany from 2002 to 2009 by jointly evaluating
available anonymous HIV and TB surveillance data sources, as
well as to characterize HIV/TB patients demographically.
Materials and Methods
The rationale of our estimation of the HIV-prevalence in TB
patients was to use an HIV surveillance instrument to identify
HIV/TB case numbers and relate them to TB notification data as
subsequently described.
HIV/TB Case Definition
We defined eligible HIV/TB patients as HIV-diagnosed
individuals living in Germany, irrespective of antiretroviral
treatment (ART) status, who presented with active culture-positive
TB (all forms) from 2002 to 2009. Individuals with history of
previous TB only were not eligible.
Data Sources
The investigated data sources comprised (i) the ClinSurv HIV
cohort; (ii) ART prescription data; and (iii) national TB
notification data of Germany (Figure 1):
(i) The ClinSurv HIV cohort is a prospective open multicentre
observational cohort study for the clinical surveillance of
HIV [23,24]. The cohort has been established in 1999 and is
maintained by collaborating HIV clinical centres in
Germany, mainly located in urban areas, and the RKI as
coordinating centre. All HIV-positive individuals presenting
in one of these clinical centres are by default enrolled in the
cohort. The data set comprises anonymous demographic
patient information (age, sex, geographic origin) and time-
related variables on clinical events, such as diagnoses of
AIDS-defining diseases including TB [25], as well as the
administered ART regimen. TB is defined by a positive
culture of M. tuberculosis complex and includes both
pulmonary and extra-pulmonary forms. The patients’ origin
was assessed as foreign, when their predominant place of
residence had been abroad (supported by information on a
foreign country of birth or foreign citizenship), and was
classified as in the European HIV Infection Data Set
(EHIDS) [26].
(ii) ART prescription data comprise prescribed daily drug doses
recorded by quarter and by Federal State of Germany. The
data set was made available by the service provider Insight
Health for 2006 to 2009.
(iii) National TB notification data result from mandatory
notification of active TB (all forms) with indication of
antituberculotic therapy, irrespective of laboratory confir-
mation [27]. For agreement with the ClinSurv HIV cohort,
the TB notification data set was restricted to culture-positive
cases.
All data sources were anonymous and independent from each
other; case-based record-linkage was not performed.
Estimation Approach
Our estimation consisted of three major steps: step 1 was to
extract TB cases among patients enrolled in ClinSurv HIV; step 2
was to assess the nationwide coverage of the ClinSurv HIV cohort;
and step 3 to determine the HIV-prevalence in TB patients in
Germany based on results from steps 1 and 2.
In step 1, the ClinSurv HIV cohort database was searched for
all patients newly diagnosed with TB from 2002 to 2009. These
annual HIV/TB case numbers were provided with a 95%
binomial exact confidence interval (CI) using the number of all
HIV-diagnosed patients presenting at the clinical centres in the
respective years as a base.
To assess the nationwide coverage of the ClinSurv HIV cohort
in step 2, we focussed on patients under ART. To quantify this
subpopulation, ART prescription data, a data source independent
from HIV notification data and thus not subject to physicians’
reporting behaviour [28], were used. The approach to derive
patient numbers from ART prescription data was established by
Kollan et al. [29]. An underlying assumption was that ART
regimen and treatment interruptions as recorded in ClinSurv HIV
apply likewise to patients outside of the cohort. To account for
patients without statutory health insurance (private, uninsured and
free medical care), whose prescriptions are not covered by Insight
Health, 15% were added to the patient numbers derived from
ART prescription data. The determined patient numbers were
contrasted with numbers of patients under ART in ClinSurv HIV
for each of the years 2006 to 2009. The resulting ratio
( = coefficient) was assessed for its robustness over time. The
average value was applied to the years 2002 to 2005, for which
ART prescription data were unavailable. We assumed that this
coefficient, determined for the subpopulation under ART, would
also approximate the share of ART naı̈ve individuals enrolled in
ClinSurv HIV of all ART naı̈ve HIV-diagnosed individuals living
in Germany.
Step 3 was to determine the HIV-prevalence in TB patients. For
each of the years 2002 to 2009, HIV/TB case numbers and their
confidence limits (step 1) were multiplied with the coefficient
determined in step 2 to project the number of HIV/TB cases for
entire Germany. These products were divided by the number of
notified culture-positive TB patients of the respective years.
To assess the 2002 to 2009 trend in the estimated HIV-
prevalence in TB patients, negative binomial regression was used
and incidence rate ratios (IRR) including 95%CIs and p-values
(5% significance level) were specified.
Analysis of HIV/TB Patient Characteristics
The HIV/TB patients enrolled in ClinSurv HIV were described
as to age, sex, and their geographical region of origin. For
continuous variables median and inter-quartile range (IQR), for
categorical variables numbers and proportions were specified.
Following a case-cohort approach, characteristics of HIV/TB
patients were contrasted with those of the entire ClinSurv HIV
Estimated HIV-Prevalence in TB Patients in Germany
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cohort enrolled until the end of 2009, as well as with all culture-
positive TB patients notified from 2002 to 2009 (pooled).
All analyses were performed using Excel (version 11, Microsoft
Corporation, Redmond, Washington, USA) and Stata (version
12.1, StataCorp LP, Texas, USA).
Ethics Statement
The ClinSurv HIV study has been approved by the Federal
Commissioner for Data Protection and Freedom of Information in
Germany. The need for written consent was waived given the
anonymous reporting of data to the RKI, the Federal Public
Health Institute of Germany. German TB notification data are
collected within the legal framework of the Protection against
Infection Act [21].
Results
From 1999 to 2009, a total of 15,531 HIV-positive individuals
were enrolled in the ClinSurv HIV cohort (recorded as of June 30,
2010). The proportion of patients under ART was 81% to 87%
from 2002 to 2009, respectively.
Patient numbers derived from ART prescription data were in
average by factor 4.8 higher than numbers of ClinSurv HIV
participants under ART. Accordingly, the ClinSurv HIV cohort
was assessed to enrol 21% of all HIV-diagnosed individuals living
in Germany.
The cohort comprised 298 HIV-positive individuals diagnosed
with culture-positive TB from 2002 to 2009 and thus classified as
HIV/TB patients. Annual HIV/TB case numbers ranged from 25
(95%CI 16–37) in 2009 to 56 (95%CI 42–73) cases in 2005.
Extrapolated to Germany overall this corresponds to 126 (95%CI
81–185) HIV/TB cases in 2009 and 270 (95%CI 204–350) cases
in 2005 (Table 1).
The estimated HIV-prevalence in notified culture-positive TB
patients was on average 4.5% in the study period. The annual
level ranged from 3.5% (95%CI 2.3–5.1%) in 2007 to 6.6%
(95%CI 5.0–8.5%) in 2005, and was 4.0% (95%CI 2.6–5.9%) in
2009 (Table 1).
Negative binomial regression revealed that the estimated HIV-
prevalence in TB patients was overall stable over time (IRR 0.99;
95%CI 0.93–1.04; p = 0.659; Figure 2); year-wise regression
analysis revealed that the 2005 estimate was an upwards outlier
(IRR 1.54; 95%CI 1.28–1.84; p,0.001) using year 2002 as
reference.
The 298 HIV/TB patients identified in the ClinSurv HIV
cohort were characterized by a male-to-female ratio of 2.1. Their
median age was 36 (IQR 30–44) years at enrolment, and 38 (IQR
31–45) years at TB diagnosis; female patients were about eight
Figure 1. Schematic overview on subpopulations and available data sources in Germany. Subpopulations of interest (in italic) include
PLWH, mostly placed under ART after HIV diagnosis, as well as TB and HIV/TB patients. Data sources (coloured boxes) include national TB notification
data restricted to culture-positive cases, ART prescription data by Insight Health, and the ClinSurv HIV cohort. TB notification and ART prescription
data capture patients irrespective of their comorbidity status. ClinSurv HIV is the only source systematically capturing both HIV and TB. This schematic
is not to scale.
doi:10.1371/journal.pone.0049111.g001
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Table 1. Data underlying the estimation of the HIV-prevalence in culture-positive TB patients in Germany, 2002 to 20091.
2002 2003 2004 2005 2006 2007 2008 2009 Overall
no. cult+ TB
notifications
4,965 4,714 4,372 4,116 3,773 3,475 3,163 3,150 31,728
no. patients in
ClinSurv HIV
7,333 7,766 8,277 8,657 8,902 9,264 9,596 9,840 15,531
no. patients in ClinSurv
HIV under ART
5,920 6,343 6,806 7,097 7,359 7,776 8,155 8,523 n.a.
Proportion of patients in
ClinSurv under ART (%)
81 82 82 82 83 84 85 87 n.a.
no. ART prescriptions n.a. n.a. n.a. n.a. 11,553,109 11,254,315 11,802,210 12,352,169 n.a.
no. patients from ART
prescriptions
n.a. n.a. n.a. n.a. 35,185 36,437 38,730 42,438 n.a.
Coefficient 4.80* 4.80* 4.80* 4.80* 4.78 4.69 4.75 4.98 4.80
no. HIV/TB cases
[95%CI]





202 [146–273] 198 [142–268] 270 [204–350] 153 [105–216] 122 [80–179] 153 [105–216] 126 [81–185] 1,430 [n.a.]
estimated
HIV-prevalence in
cult+ TB (% [95%CI])
4.3 [3.1–5.7] 4.3 [3.1–5.8] 4.5 [3.2–6.1] 6.6 [5.0–8.5] 4.1 [2.8–5.7] 3.5 [2.3–5.1] 4.8 [3.3–6.8] 4.0 [2.6–5.9] 4.5 [n.a.]
1data sources include national tuberculosis notification data, the ClinSurv HIV cohort, and ART prescription data by Insight Health; *average of the 2006 to 2009
coefficients; no. = number; n.d. = no data; n.a. = not applicable.
doi:10.1371/journal.pone.0049111.t001
Figure 2. Estimated HIV-prevalence in TB patients in Germany, 2002 to 2009. Point estimates are presented with 95% binomial exact
confidence intervals (CI). The estimated trend of the HIV-prevalence in culture-positive TB patients with 95%CI was determined by negative binomial
regression. Underlying data sources include national TB notification data, ART prescription data by Insight Health and the ClinSurv HIV cohort.
doi:10.1371/journal.pone.0049111.g002
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years younger than males. The HIV/TB patients’ geographic
origin was in 41% (117/286 with available information) German
and in 59% (169/286) foreign. A foreign origin was markedly
more frequent in women than in men (88% (80/91) versus 46%
(89/195), respectively; Table 2).
HIV/TB patient characteristics differed from those of the entire
ClinSurv HIV cohort, and from those of notified culture-positive
TB patients: The entire ClinSurv HIV cohort was characterized
by a male-to-female ratio of 4.0, a median age at enrolment of 38
(IQR 32–45) years, and by 24% (3,659/15,240) individuals of
foreign origin. Culture-positive TB patients had a male-to-female
ratio of 1.6, a median age of 48 (IQR 32–68) years at TB
diagnosis, and were in 45% born abroad (Table 2).
The age distribution of HIV/TB patients, both at enrolment
and TB diagnosis, contrasted with the age distributions of the
entire ClinSurv HIV cohort at enrolment and of the notified
culture-positive TB patients is shown in Figure 3.
The proportional distribution of regions of foreign origin
differed by sex and across HIV/TB patients, the entire ClinSurv
HIV cohort, and culture-positive TB patients as shown in Figure 4.
PLWH including HIV/TB patients of foreign origin, especially
women, were most frequently from Subsahara Africa. Foreign-
born TB patients in contrast originated more often from the
Western and Central Europe, as well as the Eastern Europe and
Central Asia regions; without marked differences between male
and female patients.
Discussion
With this study, we provide, to our knowledge, the first
nationwide estimate of the HIV-prevalence in TB patients for
Germany, as well as a demographic description of HIV/TB
patients.
Core of our estimation was a clinical HIV surveillance
instrument, the ClinSurv HIV cohort. ClinSurv HIV was the
only identified large-scale data source systematically enrolling
HIV-diagnosed individuals and capturing TB as AIDS-defining
disease including its date of diagnosis. The cohort was assessed to
enrol 21% of all HIV-diagnosed individuals living in Germany.
The estimated level of HIV in TB patients was largely stable
level around 4.5% from 2002 to 2009.
For cross-validation of our estimates we identified two
epidemiological studies providing quantitative data on HIV in
TB patients in Germany. From 2002 to 2004, a multicentre study
had been carried out by the German Central Committee against
Tuberculosis. Here, 4.3% (101/2.364) of the voluntarily inter-
viewed TB patients (unknown level of HIV testing) were
reportedly HIV-positive [30]. This was in agreement with our
nationwide 2002 to 2004 estimates of 4.3% (95%CI 3.1–5.7%),
4.3% (95%CI 3.1–5.8%), and 4.5% (95%CI 3.2–6.1%), respec-
tively. From 2007 to 2010, a smaller retrospective case series of TB
patients in Berlin prisons revealed a HIV-prevalence of 3.3% (2/
60; all tested for HIV) [unpublished data]. This was lower than our
respective 2007 to 2009 estimates of 3.5% (95%CI 2.3–5.1%),
4.8% (95%CI 3.3–6.8%), and 4.0% (95%CI 2.6–5.9%) but within
the confidence intervals.
Outside of Germany, 15 EU/EEA member states provided
2009 data on the HIV-prevalence among TB patients with known
HIV tests status to the European Centre for Disease Prevention
and Control (ECDC). Their HIV-prevalence was 7.3% (1,334/
18,181) in average, and 4.6% (43/930) in Belgium, 4.3% (9/207)
in Denmark, and 3.8% (6/160) the Czech Republic (all
neighbouring countries of Germany) [19]. Our estimate for
Germany is within the range of these levels. However, assuming
the level of HIV testing was unknown (as it is the case in Germany)
and thus all TB notifications being used as the denominator would
result in a HIV-prevalence of 3.2% (1,334/42,335) in average for
these 15 EU/EEA member states, and of 4.6% (43/944) in
Belgium, 2.7% (9/337) in Denmark, and 0.9% (6/695) in the
Czech Republic. A low proportion of HIV testing, as found for
several EU/EEA member states, influences the ascertainable
proportion of HIV among TB patients [31] and leads to an
underestimation of the comorbidity when the denominator
comprises all TB notifications.
Our estimation approach is subject to several limitations. First,
ClinSurv HIV centres are mainly based in urban areas [23]. City
States and Federal States with big cities are known to have above-
average HIV and TB notification rates in Germany [22].
Table 2. Case characteristics stratified by sex of HIV/TB patients, of the entire Clinsurv HIV cohort, and among notified culture-
positive TB patients in Germany, 2002 to 2009 (pooled data).
Patient characteristics By sex ClinSurv HIV cohort TB notification data
HIV/TB cases All HIV cases All culture-positive TB cases
Sex ratio (male-to-female) 2.1 4.0 1.6
Age at enrolment (m[IQR]
years; n)
All 36 [30–44]; n = 298 38 [32–45]; n = 15,496 n.a.
Female 31 [27–37]; n = 96 34 [28–40]; n = 3,123 n.a.
Male 39 [32–46]; n = 202 39 [33–46]; n = 12,371 n.a.
Age at TB diagnosis (m[IQR]
years; n)
All 38 [31–45]; n = 298 n.a. 48 [32–68]; n = 31,721
Female 33 [28–39]; n = 96 n.a. 48 [35–66]; n = 12,326
Male 41 [33–48]; n = 202 n.a. 46 [30–70]; n = 19,367
Proportion of foreign origin
(n/N (%))
All 169/286 (59) 3,659/15,240 (24) 13,793/30,715 (45)
Female 80/91 (88) 1,476/3,033 (49) 5,796/11,942 (49)
Male 89/195 (46) 2,183/12,207 (18) 7,976/18,745 (43)
n.a. = not applicable; m = median; IQR = inter-quartile range.
doi:10.1371/journal.pone.0049111.t002
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Moreover, the proportion of HIV-positives among TB patients
may be increased in big cities, as known from several EU/EEA
member states [32], involving potential geographical bias.
Secondly, a possible overrepresentation of individuals with AIDS
in the ClinSurv HIV cohort, related to the particular expertise of
the cohort’s clinical centres, as well as an underrepresentation of
individuals originating from HIV high-prevalence countries were
suggested by Bätzing-Feigenbaum and colleagues [23] with
unknown effect on the cohort’s representativeness for HIV/TB
among PLWH. Thirdly, diagnostic bias cannot entirely be ruled
out, e.g., a HIV testing shifted towards TB patients at (supposedly)
increased HIV risk as observed in a study in the United Kingdom
[33]. Though, universal HIV counselling and testing in TB
patients is recommended in Germany [34] and awareness is raised
on TB among PLWH [35]. Fourthly, the ClinSurv HIV cohort
focusses by definition on culture-positive TB, which may not
represent the entire TB burden among PLWH and does not
correspond to definition used in national TB notification data [27].
If all ClinSurv HIV centres had departed from their TB case
definition and considered also clinically diagnosed TB eligible, this
would result in a HIV-prevalence in TB patients of around 3.1%
for 2002 to 2009 corresponding to an overestimation of about 47%
(ranging from 41% to 54%) by restricting the denominator to
culture-positive cases.
To account for the uncertainty of our estimates we provided
them with 95% confidence intervals. No separate range of
uncertainty was, however, determined when assessing the nation-
wide coverage of ClinSurv HIV.
Beyond validity, the question arises of how important a level of
about 4.5% HIV in TB patients is for individual and public health.
In different settings, individual disease burden of HIV/TB was
assessed to be particularly high involving dual stigma [36,37],
more complex clinical manifestations [12,13], and complications
resulting from simultaneous antituberculous treatment and ART
[10,13], such as immune reconstitution inflammatory syndrome
(IRIS) [38–40] and high risk of severe liver toxicity [41]. These
aspects entail time- and resource-intensive patient care. From this
view point, the determined number of about 126 (95%CI 81–185)
HIV/TB patients in 2009 represents a non-negligible burden of
comorbidity.
Knowledge of the HIV-prevalence in TB patients is not only
important in absolute terms but to evaluate trends and epidemi-
ological patterns. We found no significant decline in the estimated
HIV-prevalence in a context of decreasing HIV/TB and TB case
numbers, but a presumably increasing HIV-prevalence in
Germany from 2002 to 2009 [28].
Our general estimate of HIV in TB patients may serve as
starting point for group-specific investigations. Evaluating demo-
graphic characteristics of HIV/TB patients indicated a shift
towards individuals of foreign origin among HIV/TB patients,
which supports earlier findings [32], and might reflect the high
HIV/TB burden in the regions of origin, mainly in Subsahara
African countries [42].
HIV/TB patients were found to have a male-to-female ratio of
2.1, which approximates the ratio of 2.7 found for 16 WHO
European region countries (pooled) in 2005 and reflects that both
Figure 3. Age distribution among individuals with HIV, TB, and HIV/TB. The HIV and HIV/TB groups refer to individuals enrolled in ClinSurv
HIV since 1999; and HIV/TB patients diagnosed with TB from 2002 to 2009. The TB group refers to notified culture-positive TB patients in Germany,
2002 to 2009 (pooled data).
doi:10.1371/journal.pone.0049111.g003
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infectious diseases are more prevalent in the male population in
the European region [2]. A systematic review of HIV/TB
comorbidity in the EU/EEA identified an increased risk of
HIV/TB in male TB patients [32]. This is also supported by our
identified male-to-female ratio of 1.6 among TB patients being
lower than among HIV/TB patients (ratio 2.1). More pro-
nounced, however, was the overrepresentation of women among
HIV/TB patients in relation to all PLWH enrolled in ClinSurv
HIV (ratio 4.0). TB as AIDS-defining disease was only slightly
more frequent in women according to HIV/AIDS notification
data of EU/EEA member states [43]. Sex ratios, however, might
be influenced by the patients’ geographic origins and their
respective epidemiological patterns suggesting the need for
multivariable approaches for correct interpretation.
Our study, estimating the HIV-prevalence in TB patients by
joint evaluation of available anonymous HIV and TB surveillance
data sources, enhances rather than suspends the need for an
integrated HIV/TB notification within the national TB surveil-
lance system in Germany. Only this would allow group-specific
analyses and the assessment of for instance treatment outcomes
and drug-resistance in both HIV-positive and HIV-negative TB
patients. Such quantitative evidence is needed to monitor progress
in TB control [44], to further define risk-groups for HIV/TB and
target interventions accordingly, as well as to design further
operational research [3].
Yet, already today, our developed approach for estimating the
HIV-prevalence in TB patients is valuable for epidemiological
monitoring of HIV/TB and applicable within the current legal
frameworks.
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